Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | NAAA | Q02083 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821203 | 0.93 | PDE4A (0.32) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12823496 | 0.90 | PTGS2 (0.35) | ESR1NAAAAPP | |
| SCHEMBL12823044 | 0.88 | PDE4A (0.30) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12823491 | 0.88 | PDE4A (0.30) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12718722 | 0.88 | PDE4A (0.32) | NAAAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12822601 | 0.86 | ESR1 (0.31) | ESR1GRIN2B | |
| SCHEMBL12718812 | 0.85 | NAAA (0.34) | ESR1NAAAPDE4APDE4BPDE4C | |
| SCHEMBL12822705 | 0.85 | NAAA (0.34) | ESR1NAAAPDE4APDE4BPDE4C | |
| SCHEMBL10303254 | 0.85 | PDE4D (0.35) | NAAAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12823116 | 0.85 | GRIN2B (0.32) | NAAAPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | ESR1 1665/4885NAAA 3997/4885PDE4A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.